Construct validity of medicare chemotherapy claims: the case of 5FU.
about
Identifying specific chemotherapeutic agents in Medicare data: a validation studyComparison of SEER Treatment Data With Medicare Claims.Accuracy of using Diagnosis Procedure Combination administrative claims data for estimating the amount of opioid consumption among cancer patients in Japan.Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicityAnalytical strategies for characterizing chemotherapy diffusion with patient-level population-based data.Predictors of venous thromboembolism in patients with advanced common solid cancersHospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802).Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344)Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participantsValidity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposureValidation of electronic data on chemotherapy and hormone therapy use in HMOs.Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancerSurvival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population.Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.Completion of therapy by Medicare patients with stage III colon cancer.Late gastrointestinal toxicities following radiation therapy for prostate cancer.Automated matching software for clinical trials eligibility: measuring efficiency and flexibilityAssessing the impact of screening colonoscopy on mortality in the medicare populationThe impact of venous thromboembolism on risk of death or hemorrhage in older cancer patientsReferral to medical oncology: a crucial step in the treatment of older patients with stage III colon cancer.Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002?Adjuvant intravesical bacillus calmette-guérin therapy and survival among elderly patients with non-muscle-invasive bladder cancerIntended versus inferred management after PET for cancer restaging: analysis of Medicare claims linked to a coverage with evidence development registry.External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews.Effect of a dementia diagnosis on survival of older patients after a diagnosis of breast, colon, or prostate cancer: implications for cancer care.Severe genitourinary toxicity following radiation therapy for prostate cancer--how long does it last?Esophagectomy compared with chemoradiation for early stage esophageal cancer in the elderlyIdentifying cancer drug regimens in French health insurance database: An application in multiple myeloma patients.Reasons for underuse of recommended therapies for colorectal and lung cancer in the Veterans Health Administration.
P2860
Q30413422-F009C49A-48FF-4E03-8AA3-5720EAD46902Q30779910-D2974B95-717A-4674-8952-6CF17E82BB72Q30992942-25815B9C-3152-4F99-BFEE-ED12435DE605Q33367028-2CA00282-D8DB-4189-B501-FF9E51870CFBQ33520977-55F3D47E-663A-4D18-A243-AE997F1EC844Q33810510-475B1BE7-B533-4406-82F0-AA69C04406FAQ33992552-E77F083A-F69A-4988-A428-265AF9732C2BQ34150886-8F6FDF67-BB37-4668-89C6-D14EB4F2BF4EQ34150896-ADC62757-0CC8-4292-A8E4-497FDA5A4A7DQ34159971-1308861B-462A-42BA-9A1D-DE627BFB4823Q34244526-B44B3A86-C124-4B5F-B9C9-F5487E769E3CQ34613130-C7EE6D0D-2285-4B40-A37D-126ADF5822B7Q35011194-FDB16576-45EA-475D-95E0-4A7849DF73DDQ35043089-D40921EE-E92E-4E78-AC5D-E70292E01868Q35071455-B20A78E6-E510-4A41-BECF-9CCB0DA98FAEQ35256076-2F774851-1D96-49E5-A087-80B028C37C7FQ35295289-A1CAFCD6-BE69-47EF-8A65-77A157DC5E54Q35606871-AEA8BE1B-8403-461E-9D47-DF4FD47C14E2Q35683034-94E0B5DF-26CE-493B-A571-CA649B866CBCQ35878821-DEE0AAA5-812A-40C3-AF71-B931AA27F9FEQ36503071-6F5C3A37-4D19-45E1-832A-BB2062270109Q36678207-683C04A1-C959-463A-AEA7-4B17413DED0DQ36869758-8170F60C-5A81-4C10-AF7F-74729FDF21EFQ36936083-2DF4AB62-F70A-4533-8B51-E739CF8FA5BCQ37189241-CE658C14-9B76-40EE-9D7A-AC20912E53E6Q37284915-305E22D9-F13E-445E-B924-BCB531201606Q37399708-CC123CB0-05A5-47FA-A9BA-68E5D7E3D2B2Q38660850-8C8FA0BF-3AC5-46D6-A0AB-76E6ABE6CDA8Q45330394-186F4767-8CC3-4025-9E57-6D3ECE906DB1
P2860
Construct validity of medicare chemotherapy claims: the case of 5FU.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Construct validity of medicare chemotherapy claims: the case of 5FU.
@ast
Construct validity of medicare chemotherapy claims: the case of 5FU.
@en
Construct validity of medicare chemotherapy claims: the case of 5FU.
@nl
type
label
Construct validity of medicare chemotherapy claims: the case of 5FU.
@ast
Construct validity of medicare chemotherapy claims: the case of 5FU.
@en
Construct validity of medicare chemotherapy claims: the case of 5FU.
@nl
prefLabel
Construct validity of medicare chemotherapy claims: the case of 5FU.
@ast
Construct validity of medicare chemotherapy claims: the case of 5FU.
@en
Construct validity of medicare chemotherapy claims: the case of 5FU.
@nl
P2093
P1433
P1476
Construct validity of medicare chemotherapy claims: the case of 5FU.
@en
P2093
Diane S Lauderdale
Elizabeth B Lamont
Nicholas A Christakis
Richard L Schilsky
P304
P356
10.1097/00005650-200203000-00004
P577
2002-03-01T00:00:00Z